Médecine

Paramédical

Autres domaines


S'abonner

Drug samples in dermatology: Special considerations and recommendations for the future - 24/04/13

Doi : 10.1016/j.jaad.2009.07.053 
Ali Alikhan, MD a, , Mary Sockolov, BS a, Robert T. Brodell, MD b, c, d, Steven R. Feldman, MD e
a University of California at Davis, School of Medicine, Sacramento, California 
b Northeastern Ohio Universities College of Medicine, Rootstown, Ohio 
c Case Western Reserve University School of Medicine, Cleveland, Ohio 
d University of Rochester School of Medicine and Dentistry, Rochester, New York 
e Department of Dermatology, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina 

Reprint requests: Ali Alikhan, MD, 3605 Paseo Primario, Calabasas, CA 91302.

See related commentary on page 1062

Abstract

Background

The use of drug samples is a controversial issue in medicine.

Objective

We sought to determine the pros and cons of drug sampling, and how drug sampling in general medicine differs from dermatology.

Methods

Literature searches were conducted on PubMed, Google, and Yahoo!. Articles were found pertaining to drug sampling in general, and for dermatology specifically.

Results

Numerous pros and cons for drug sampling were found in the literature search. We divided these by cost-related issues, such as the industry-wide cost of sampling and the use of sampling to assist the underinsured and poor, and quality of care issues, such as adherence, patient education, and safety considerations. Articles also suggested that dermatology may differ from general medicine as topical treatments have fewer side effects, are more complicated to use, and come in different vehicles.

Limitations

We identified few studies specifically focused on issues relevant to sampling in dermatology.

Conclusion

There are strong arguments for and against drug sampling involving both cost and quality of care issues. Dermatology-specific medications clearly differ from oral medications in several regards. We ultimately conclude that the benefits of drug sampling outweigh the risks, but give recommendations on how drug sampling can be done ethically and effectively, including limiting personal use, not selling samples, properly documenting sample release, teaching patients about proper use, teaching students and residents ethical use of samples, working with pharmaceutical representatives in an ethical manner, prescribing the drug that is best for the patient, and securing samples appropriately to prevent theft and misuse.

Le texte complet de cet article est disponible en PDF.

Key words : drugs, industry, pharmaceuticals, samples, sampling

Abbreviations used : AMA, CMI, MeSH, PhRMA


Plan


 The first two authors contributed equally to the article.
 Funding sources: None.
 Disclosure: Dr Brodell has received research, speaking, and/or consulting support from Allergan, Janssen, Pfizer, Novartis, Squib, Galderma, 3M/Graceway, Sirius, Medicis, Amgen, Dusa, UpJohn, Connetics, GlaxoSmithKline, Dermik, Genentech, CollagGenex, Pedinol, Stiefel, Aventis, Doak, and OrthoNeutrogena; he dispenses drug samples in his practice. Dr Feldman has received research, speaking, and/or consulting support from Abbott, Amgen, Arcutis, Astellas, Aventis, Caremark, Centocor, Doak, Galderma, Genentech, Kikakua, Merck, Merz, National Biological Corp, Novartis, Peplin, Photomedex, Skin Medica, Stiefel, Suncare Research, and Warner Chilcott; The Center for Dermatology Research at Wake Forest University Baptist Medical Center is funded by a grant from Galderma Laboratories LP; he dispenses drug samples in his practice. Dr Alikhan and Ms Sockolov have no conflicts of interest to declare.


© 2010  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 62 - N° 6

P. 1053-1061 - juin 2010 Retour au numéro
Article précédent Article précédent
  • Rosaceiform dermatitis associated with topical tacrolimus treatment
  • Shoko Fujiwara, Yukari Okubo, Ryokichi Irisawa, Ryoji Tsuboi
| Article suivant Article suivant
  • Individual drug sampling does not supplant the need for head-to-head trials in dermatology
  • Jack S. Resneck, Marta VanBeek

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.